GSK unveils positive trial results for vaccine against RSV

The trial showed the adjuvanted vaccines efficacy against lower respiratory tract disease caused by RSV in adults over 60 throughout multiple RSV seasons and when revaccinated annually.

The cumulative efficacy over two seasons against RSV-LRTD was put at 67.2% and at 78.8% when it came to severe LRTD.

"Our goal is to provide a high level of protection for older adults most at risk from RSV," said Tony Wood, chief scientific officer at GSK.

"These data show the efficacy of a single dose of our vaccine over two RSV seasons against RSV-LRTD, including in the populations most at risk due to age or underlying medical conditions. This reinforces our confidence in its potential to make a significant public health impact."

Arexvy's efficacy during the first season of RSV - the study's primary endpoint - was put at 82.6% and 94.1% in the case of severe LRTD.

As of 0917 BST, shares of GS were dipping by 0.22% to 1,358.60p.